Trial Profile
An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms FIRST
- Sponsors Roche
- 30 Oct 2015 Results of biomarker sub-study (n=154) published in the Clinical and Experimental Rheumatology
- 11 Apr 2014 New trial record